Oxbryta Lawsuit 2026: Pfizer Withdrew the Sickle Cell Drug — Who Can Still File & What the June 2027 Trial Means
Direct answer: Yes — Oxbryta lawsuits are still being filed in 2026. Pfizer voluntarily withdrew the sickle cell drug worldwide on September 25, 2024, after data showed an imbalance of vaso-occlusive crises and fatal events. Injured patients and families are now suing Pfizer and Global Blood Therapeutics in individual claims — there is no MDL and no global settlement yet, but the first trial is scheduled for June 7, 2027, and at least one wrongful-death claim was already resolved in late 2025 on undisclosed terms.
- Key fact 1: The FDA granted Oxbryta accelerated approval in 2019; in December 2021 it extended approval to children as young as 4 years old.
- Key fact 2: Pfizer acquired Global Blood Therapeutics, Oxbryta's original developer, in October 2022 — two years before the withdrawal.
- Key fact 3: Pfizer's September 25, 2024 withdrawal was voluntary and global: "the overall benefit of Oxbryta no longer outweighs the risk," citing an imbalance in vaso-occlusive crises and fatal events.
- Key fact 4: Federal Oxbryta cases are coordinated before Judge Trina L. Thompson in the Northern District of California; the lead case, Allen v. Global Blood Therapeutics, has expert and summary-judgment motions due December 11, 2026 and trial set for June 7, 2027.
- Key fact 5: On September 14, 2026, a Mississippi mother filed a wrongful-death suit alleging Oxbryta caused vaso-occlusive crises that sent blood clots to her 8-year-old son's heart and lungs.
The drug and the promise
Oxbryta (voxelotor) is a prescription medication developed for sickle cell disease — a genetic blood disorder in which red blood cells deform into a sickle shape, obstructing blood flow and causing intense pain and potential organ damage. It was the first medication approved to address the root causes of the disease: it was designed to improve hemoglobin levels, help blood cells retain more oxygen, and prevent vaso-occlusive crises (VOCs), which are painful episodes in which sickled red blood cells block blood flow and trigger an inflammatory response in the chest, back, and limbs.
The FDA granted Oxbryta accelerated approval in 2019 on the strength of phase-3 trial data suggesting it raised hemoglobin and reduced hemolysis. In December 2021, the agency extended that approval down to children as young as four. For a community that had lived with few treatment options, the drug arrived as a genuine advance — which is exactly what makes the next chapter so painful for the families now filing suit.
Why Pfizer pulled it
Over time, the FDA and the manufacturers began receiving a growing number of reports from Oxbryta users who suffered vaso-occlusive crises — the very episodes the drug was supposed to prevent — at rates much higher than expected. On September 25, 2024, Pfizer announced it was voluntarily withdrawing Oxbryta from the market worldwide and discontinuing all clinical trials, stating: "Pfizer's decision is based on the totality of clinical data that now indicates the overall benefit of Oxbryta no longer outweighs the risk in the approved sickle cell patient population. The data suggest an imbalance in vaso-occlusive crises and fatal events which require further assessment."
The FDA issued a safety alert on September 26, 2024 and advised patients to consult their healthcare providers about alternative treatments. The label's listed common side effects — headache, diarrhea, abdominal pain, nausea, rash or hives, fever — never included vaso-occlusive crises, stroke, organ failure, or death, and that gap is now the heart of the litigation.
Who is eligible to file
Lawyers reviewing Oxbryta claims are focused on individuals who were prescribed Oxbryta (or received it in a clinical trial) and afterward suffered one of the injuries the withdrawal was based on: increased vaso-occlusive crises or pain crises, stroke or neurological injury, organ damage, hospitalization from treatment complications, or death potentially linked to the drug. This includes family members of patients who died — wrongful-death and survival claims are a significant part of the docket, and an estate case filed in 2024 remains active in San Francisco courts (Case No. CGC-24-621022).
A critical clarification, because the internet is full of misleading pages: there is no class action, no settlement fund, and no simple claim form. These are individual product-liability claims that must be evaluated and filed by an attorney. Anyone promising otherwise is not describing this litigation.
For context on how drug-injury litigation works when a medication is pulled from the market, see our guides to the Invokana amputation litigation and the Actos bladder-cancer settlement history.
The litigation: no MDL, one coordination
Unlike most large drug litigations, there is no multidistrict litigation for Oxbryta. The federal cases are instead proceeding as related individual suits before Judge Trina L. Thompson in the U.S. District Court for the Northern District of California, with the parties filing joint case-management statements to coordinate discovery. The named defendants are Pfizer Inc. and Global Blood Therapeutics, Inc.
The complaints share a common theory: that the manufacturers aggressively promoted Oxbryta as safe and effective while failing to disclose real-world evidence that it was associated with increased vaso-occlusive crises, strokes, and deaths — and that patients and physicians would have made different decisions with full information. Defenses will likely center on FDA-approved labeling and the argument that causation is unproven, but that is for the courts to decide; the important point for potential claimants is that the litigation is in its middle stages, not at its end.
The 2026 calendar that matters
The lead case, Allen v. Global Blood Therapeutics (N.D. Cal.), has expert and summary-judgment motions due December 11, 2026, with trial scheduled for June 7, 2027. A second case, Ford, follows with trial on September 13, 2027. These early trials will do for Oxbryta what bellwether trials do in an MDL: give both sides their first look at how juries respond to the evidence, and set the tone for any settlement negotiations that follow.
New cases continue to be filed. In December 2025, Laura Christine Matteliano-Madu sued after her husband, who began taking Oxbryta in a clinical trial in 2021, died following a life-threatening vaso-occlusive crisis. On September 14, 2026, Mocha Myers of Mississippi filed a wrongful-death complaint alleging that Oxbryta-related crises caused blood clots that traveled to her 8-year-old son's heart and lungs. And in late 2025, Pfizer resolved at least one Oxbryta wrongful-death claim on undisclosed terms — a reminder that resolution activity can begin long before a global program exists.
The deadline problem
Statutes of limitations are running. Plaintiffs argue that filing deadlines should be tolled because the manufacturers concealed the risks — a fraudulent-concealment theory — but tolling is an argument made in court, not a guarantee. In September 2024, the withdrawal itself started the clock in many states, and courts have not agreed on how the discovery rule applies to each claimant's facts.
The practical implication is blunt: waiting for the June 2027 trial, or for news of a global settlement, can end a claim before anyone evaluates it. Preserve your records now — pharmacy records showing when Oxbryta was prescribed and for how long, hospital and emergency records of every crisis or hospitalization after starting the drug, and documentation of any diagnosis of stroke or organ injury.
Watch the Problem Solved channel on YouTube for clear explanations of consumer and health topics like this one.
What a strong claim looks like
No honest attorney can promise an outcome — there is no settlement program and no track record of verdicts in this litigation yet. What reviewers look for is straightforward: documented Oxbryta use, a clear before-and-after pattern in your medical records (crises increasing or appearing after the drug began), and a serious injury of the kind the withdrawal was based on. The strongest files have complete pharmacy records, dated hospital records, and a treating physician's notes connecting the dots.
General information only — not legal or medical advice. If you were prescribed Oxbryta, speak with your doctor about your care and with a qualified attorney about your rights. Do not restart a withdrawn medication without medical guidance.
Who Benefits From This — and Who Does Not
This article is for sickle cell patients and families weighing whether an Oxbryta injury claim still exists after Pfizer's worldwide withdrawal — and for readers who want to avoid the signup-form myth around it.
Who benefits:
- Sickle cell patients who took Oxbryta and suffered increased vaso-occlusive crises, stroke, organ damage, hospitalization, or a death linked to the drug: eligibility turns on documented use and documented injury, not on how long you took it. How to use this article: assemble medical records showing both use and injury.
- Families and estates of patients who died after taking Oxbryta: wrongful-death and survival claims are a significant part of this litigation, including an active estate case in San Francisco courts. How to use this article: have the estate's records reviewed promptly, since time limits still apply.
- Readers tracking the calendar: there is no MDL and no global settlement yet, but the first trial is scheduled for June 7, 2027, and at least one wrongful-death claim was already resolved in late 2025 on undisclosed terms. How to use this article: use that calendar to judge any urgency claim made to you.
Who does not benefit:
- People who took Oxbryta without a documented injury: without documented use plus documented injury, the article describes no claim.
- Anyone looking for a class-action form or settlement fund: there is no class action, no settlement fund, and no claim form — cases are individual lawsuits filed by private attorneys.
- Anyone still holding unused Oxbryta and hoping to restart it: Pfizer withdrew the drug worldwide on September 25, 2024; do not restart it on your own — talk to your doctor about alternatives.
Frequently asked questions
Is the Oxbryta lawsuit a class action I can join online?
No. There is no class action, no settlement fund, and no claim form. Oxbryta cases are individual product-liability lawsuits filed by private attorneys. Anyone offering a simple sign-up-and-wait-for-a-check form is not describing this litigation.
I still have unused Oxbryta at home. What should I do with it?
Do not restart a withdrawn medication on your own. Pfizer withdrew Oxbryta worldwide in September 2024, and the FDA advised patients to consult their healthcare providers about alternative treatments. Talk to your doctor promptly about your care.
Can I file if I only took Oxbryta for a short time?
Eligibility turns on documented use and a documented injury — increased vaso-occlusive crises, stroke, organ damage, hospitalization, or death linked to the drug — not on how long you took it. Short use does not disqualify a claim, but your medical records must support causation.
My family member died after taking Oxbryta. Can the estate still file?
Yes — wrongful-death and survival claims are a significant part of this litigation, including an active estate case in San Francisco courts. Time limits still apply to estates, so a qualified attorney should review the case promptly.
Who benefits most from this Oxbryta article?
Sickle cell patients with documented Oxbryta use and a documented injury — increased crises, stroke, organ damage, hospitalization, or death — and estates of patients who died after taking the drug, since wrongful-death and survival claims are a significant part of this litigation.
How do I start an Oxbryta claim review?
Gather records proving Oxbryta use and the injury, talk to your doctor promptly about alternative treatment (never restart a withdrawn drug on your own), and ask a qualified attorney to review the case promptly, keeping in mind the June 7, 2027 first-trial date and the applicable time limits.